Altimmune Q2 FY26 net loss narrows to $22.8 million; cash and investments climb to $519 million
ALT•Cash position increases
Cash, cash equivalents and investments totaled $519 million as of June 30, 2026.
Clinical program updates
Altimmune initiated the PERFORMA Phase 3 MASH trial; 52-week data readout is anticipated in 2029.
The RECLAIM Phase 2 AUD trial met its primary endpoint, and RESTORE Phase 2 ALD enrollment was completed with topline data expected in H2 2027.
Quarterly loss narrows as expenses rise
Altimmune posted a net loss of $22.8 million, or $0.12 a share, for the quarter ended June 30, 2026.
Research and development expense rose to $18.7 million from $17.2 million a year earlier, due to ALD trial activity and PERFORMA Phase 3 startup costs.
General and administrative expense increased to from on higher professional services and compensation.
